Carmustine
 | |
 | |
| Names | |
|---|---|
| IUPAC name
1,3-Bis(2-chloroethyl)-1-nitrosourea[1] | |
| Other names
N,N’-Bis(2-chloroethyl)-N-nitrosourea | |
| Identifiers | |
154-93-8  | |
| ChEBI | CHEBI:3423 |
| ChEMBL | ChEMBL513 |
| ChemSpider | 2480 |
| DrugBank | DB00262 |
| EC Number | 205-838-2 |
| Jmol interactive 3D | Image |
| KEGG | D00254  |
| MeSH | Carmustine |
| PubChem | 2578 |
| RTECS number | YS2625000 |
| UNII | U68WG3173Y |
| UN number | 2811 |
| |
| |
| Properties | |
| C5H9Cl2N3O2 | |
| Molar mass | 214.05 g·mol−1 |
| Appearance | Orange crystals |
| Odor | Odourless |
| Melting point | 30 °C (86 °F; 303 K) |
| log P | 1.375 |
| Acidity (pKa) | 10.194 |
| Basicity (pKb) | 3.803 |
| Pharmacology | |
| ATC code | L01 |
| Hazards | |
| GHS pictograms |   |
| GHS signal word | DANGER |
| H300, H350, H360 | |
| P301+310, P308+313 | |
| EU classification (DSD) |
 T+ |
| R-phrases | R45, R46, R60, R61, R28 |
| S-phrases | S22, S36/37/39, S45 |
| Lethal dose or concentration (LD, LC): | |
| LD50 (Median dose) |
20 mg kg−1 (oral, rat) |
| Related compounds | |
| Related ureas |
Dimethylurea |
| Related compounds |
|
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| verify (what is ?) | |
| Infobox references | |
Carmustine (bis-chloroethylnitrosourea, BCNU, BiCNU) is a medication used mainly for chemotherapy and sometimes for immunosuppression before transplant. It is a nitrogen mustard β-chloro-nitrosourea compound used as an alkylating agent. As a dialkylating agent, BCNU is able to form interstrand crosslinks in DNA, which prevents DNA replication and DNA transcription.
It has the appearance of an orange-yellow solid.
Carmustine for injection was earlier marketed under the name BiCNU by Bristol-Myers Squibb[2] and now by Emcure Pharmaceuticals.[3] In India it is sold under various brand names including Consium .
Uses
It is used in the treatment of several types of brain cancer (including glioma, glioblastoma multiforme, medulloblastoma and astrocytoma), multiple myeloma and lymphoma (Hodgkin's and non-Hodgkin). BCNU is sometimes used in conjunction with alkyl guanine transferase (AGT) inhibitors, such as O6-benzylguanine. The AGT-inhibitors increase the efficacy of BCNU by inhibiting the direct reversal pathway of DNA repair, which will prevent formation of the interstrand crosslink between the N1 of guanine and the N3 of cytosine.
It is also used as part of a chemotherapeutic protocol in preparation for hematological stem cell transplantation, a type of bone marrow transplant, in order to reduce the white blood cell count in the recipient (patient). Use under this protocol, usually with Fludarabine and Melphalan, was coined by oncologists at the University of Texas MD Anderson Cancer Center.
Implants
In the treatment of brain tumours, the U.S. Food and Drug Administration (FDA) approved biodegradable discs infused with carmustine (Gliadel).[4] They are implanted under the skull during a surgery called a craniotomy.[5] The disc allows for controlled release of carmustine in the extracellular fluid of the brain, thus eliminating the need for the encapsulated drug to cross the blood-brain barrier.[6]
See also
References
- ↑ CID 2578 from PubChem
- ↑ http://www.bms.com/news/features/2012/Pages/CompanyStatementonBiCNU.aspx
- ↑ Emcure Press release
- ↑ Ewend MG, Brem S, Gilbert M; et al. (June 2007). "Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control". Clin. Cancer Res. 13 (12): 3637–41. doi:10.1158/1078-0432.CCR-06-2095. PMID 17575228.
- ↑ http://www.cancerbackup.org.uk/Treatments/Chemotherapy/Individualdrugs/Gliadelimplants
- ↑ http://www.hopkinsmedicine.org/hmn/W05/feature3.cfm
External links
| ||||||||||||||||||||||||||||||||||||||